In patients who develop adenocarcinomas, there is typically a
progression from normal epithelium, through some inflammatory, metaplastic, or other
intermediate stage, to dysplasia and invasive cancer. The progression is by no
means invariable and indeed may be reversible. Colorectal cancer exemplifies
this progression and serves as an excellent model for investigating
opportunities in cancer prevention by means of various secondary (eg,
polypectomy to remove the precursor adenoma) and primary (chemoprevention)
We and many others have begun to explore opportunities in colon
cancer chemoprevention through clinical trials involving groups at increased
risk of colorectal cancer: patients with familial adenomatous polyposis,
hereditary nonpolyposis colorectal cancer, and sporadic adenoma. This article
briefly reviews data from our large trial of a selective COX-2 inhibitor,
describes the designs for our current hereditary nonpolyposis colorectal cancer
and familial adenomatous polyposis trials (as well as ongoing sporadic adenoma
trials), and includes comments on trials with other agents.
Patients with familial adenomatous polyposis have a germline
mutation in the adenomatous polyposis coli (APC) gene. The consequence of
this is the development of hundreds of adenomas, typically during adolescence.
If untreated, as by prophylactic colectomy
or proctocolectomy, the risk of colorectal cancer is nearly 100%. Following
colectomy, subjects remain at risk of duodenal carcinoma and, if proctectomy is
not performed, of rectal cancer; these areas have hence been targeted in
surveillance and chemoprevention interventions.
Historically, cancer prophylaxis has consisted of colectomy
followed by proctosigmoidoscopic surveillance and ablation of recurrent rectal
polyps, or more recently and aggressively, prophylactic proctocolectomy with
restorative ileal pouch reservoir/anal anastomosis. Management of risk of
duodenal neoplasia has been particularly vexing because of the variable natural
history of duodenal adenomas; the lack of effective, safe endoscopic measures to
ablate the flat, spreading lesions; and the morbidity associated with aggressive
surgical interventiontypically pancreaticoduodenectomy.
Though prophylactic surgical interventions are well accepted in
familial adenomatous polyposis, the possibility of medical approaches has been
explored. The nonsteroidal anti-inflammatory drug (NSAID) sulindac has been
reported to cause complete or near-complete regression of rectal adenomas,
initially in uncontrolled trials[2-4] and later in placebo-controlled
investigations. More modest regression of rectal adenomas has been reported
in two larger placebo-controlled studies.[6,7] No cases of complete regression
were observed, and adenomas recurred within several months of cessation of the
sulindac.[5,6] No long-term efficacy studies of sulindac have been carried out,
and there are case reports of cancers occurring while taking sulindac.
Hereditary nonpolyposis colorectal cancer has until recently
been a clinical diagnosis involving the familial pattern of early-onset and/or
multiple primary colorectal cancer, with or without the presence of certain
extracolonic tumors. In many families colon tumors cluster in the right colon.
Adenomas may be completely absent and rarely number more than a few. The mode of
inheritance for hereditary nonpolyposis colorectal cancer is autosomal dominant,
with penetrance for colorectal cancer estimated at about 80% by age 70. The mean
age at cancer onset is approximately 45 years but ranges from 20 to 80+ years,
thus overlapping with the age distribution of sporadics.
Stomach and small bowel adenocarcinomas occur in excess, but are
sufficiently infrequent that surveillance is not usually recommended. In
addition to colorectal and other gastrointestinal tumors, hereditary
nonpolyposis colorectal cancer includes a number of extraintestinal tumors.
Lacking any pathognomonic features, the significance of any given tumor in a
particular patient is problematic. Tumors most commonly involve the endometrium,
followed by the ovary and the uroepithelium (ureter and renal pelvis). Peculiar
skin tumors (sebaceous adenoma, carcinoma, and keratoacanthoma) occur in a
subset of families with the so-called Muir-Torre syndrome.
As in familial adenomatous polyposis, the management of
hereditary nonpolyposis colorectal cancer involves recognition of risk, followed
by appropriate surveillance and surgical intervention. All must be enhanced,
compared to the average-risk patient. In a sufficiently striking family,
colorectal cancer risk to offspring of affected parents approaches 50%.
Molecular genetic testing will detect mutations in one of the "hereditary
nonpolyposis colorectal cancer genes" in up to 85% of families.
Assuming such a mutation is identified, offspring of affected
parents can be segregated into two groups: those at population risk
(noncarriers) and those whose risk approaches 100% (carriers). In carriers,
colonoscopy is recommended, beginning at age 20 to 30 and repeated at intervals
of 1 to 5 years (the broad range reflects a lack of hard data and a lack of
consensus among experts). Noncarriers will require no further enhanced
evaluation, assuming accuracy of the genetic testing.
When adenocarcinomas are detected, subtotal colectomy with
ileorectal anastomosis is urged. Residual risk to the rectum exists
postcolectomy, but its magnitude is uncertain and probably not great enough to
warrant proctectomy. The approach to the patient with an adenoma is uncertain.
Most would perform simple endoscopic polypectomy, but the possibility of
prophylactic colectomy may be increasingly considered in known mutation
carriers, particularly when difficult-to-remove right-sided sessile lesions are
involved. Surveillance for extracolonic tumors has received little attention.
The chronology of molecular advances in hereditary nonpolyposis
colorectal cancer is interesting. Unlike familial adenomatous polyposis, there
was no good clue as to the possible location of a susceptibility locus, though
several "candidate" loci, such as the APC, p53, and DCC (deleted in
colorectal carcinoma) genes, were evaluated and excluded. Rather, establishing
genetic linkage in hereditary nonpolyposis colorectal cancer required a search
through the human genome, facilitated by the developing library of known, linked
In 1993 such linkage was established to a locus on chromosome 2
and quickly confirmed. Within a year, the gene had been cloned and found to show
homology in nucleotide sequence to a member of a yeast DNA "mismatch
repair" gene (MutS). Because linkage studies at this locus had failed to
account for a majority of families that appeared to have hereditary nonpolyposis
colorectal cancer, additional loci were evaluated and a second gene identified.
When cloned, this gene was also found to show homology to a member of the yeast
mismatch repair family of genes.
It was then concluded that perhaps other human genes from this
mismatch repair family might also account for cases of hereditary nonpolyposis
colorectal cancer. The library of human DNA sequences was searched to determine
if there were other areas that showed significant homology to the other
representatives of the mismatch repair genes of lower species. Several
additional human mismatch repair genes were identified and found to account for
a small proportion of hereditary nonpolyposis colorectal cancer families.
As in the case of familial adenomatous polyposis, each of these
discoveries carried potential implications for management. Establishment of
linkage enabled recognition of carriers of susceptibility through performance of
linkage analysis utilizing polymorphic flanking markers. Cloning of the genes
enabled direct testing of individual affected members of hereditary nonpolyposis
colorectal cancer families, without having to resort to linkage analysis.
1. Kinzler KW, Nilbert MC, Su LK, et al: Identification of FAP
locus genes from chromosome 5q21. Science 253:661-665, 1991.
2. Waddell WR, Loughry RW: Sulindac for polyposis of the colon.
J Surg Oncol 24:83-87, 1983.
3. Rigau J, Pique JM, Rubio E, et al: Effects of long-term
sulindac therapy on colonic polyposis. Ann Intern Med 115:952-954, 1991.
4. Winde G, Schmid KW, Schlegel W, et al: Complete reversion and
prevention of rectal adenomas in colectomized patients with familial adenomatous
polyposis by rectal low-dose sulindac maintenance treatment. Advantages of a
low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas
exceeding 33 months. Dis Colon Rectum 38:813-830, 1995.
5. Labayle D, Fischer D, Vielh P, et al: Sulindac causes
regression of rectal polyps in familial adenomatous polyposis. Gastroenterology
6. Giardiello FM, Stanley RH, Krush AJ, et al: Treatment of
colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N
Engl J Med 328:1313-1316, 1993.
7. Nugent KP, Farmer KC, Spigelman AD, et al: Randomized
controlled trial of the effect of sulindac on duodenal and rectal polyposis and
cell proliferation in patients with familial adenomatous polyposis. Br J Surg
8. Niv Y, Fraser GM: Adenocarcinoma in the rectal segment in
familial polyposis coli is not prevented by sulindac therapy. Gastroenterology
9. Cats A, Kleibeuker JH, van der Meer R, et al: Randomized,
double-blinded, placebo-controlled intervention with supplemental calcium in
families with hereditary nonpolyposis colorectal cancer. J Natl Cancer Inst
10. Burn J, Chapman PD, Mathers J, et al: The protocol for a
European double-blind trial of aspirin and resistant starch in familial
adenomatous polyposis: The CAPP study. Concerted Action Polyposis Prevention.
Eur J Cancer 31A:1385-1386, 1995.
11. Burn J, Chapman PD, Bishop DT, Mathers J: Diet and cancer
prevention: The Concerted Action Polyp Prevention (CAPP) studies. Proc Nutr Soc
12. Kune GA, Kune S, Watson LF: Colorectal cancer risk, chronic
illnesses, operations, and medications: Case control results from the Melbourne
Colorectal Cancer Study. Cancer Res 48:4399-4404, 1988.
13. Thun MJ, Namboodiri MM, Heath Jr CW: Aspirin use and reduced
risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991.
14. Rosenberg L, Palmer JR, Zauber AG, et al: A hypothesis:
Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer.
J Natl Cancer Inst 83:355-358, 1991.
15. Giovannucci E, Rimm EB, Stampfer MJ, et al: Aspirin use and
the risk for colorectal cancer and adenoma in male health professionals. Ann
Intern Med 121:241-246, 1994.
16. Pollard M, Luckert PH: Indomethacin treatment of rats with
dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 64:1323-1327,
17. Reddy BS, Rao CV, Rivenson A, et al: Inhibitory effect of
aspirin on azoxymethane-induced colon carcinogenesis in F344 rats.
Carcinogenesis 14:1493-1497, 1993.
18. Wolfe MM, Lichtenstein DR, Singh G: Gastrointestinal
toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1897,
19. Vane JR, Botting RM: Mechanism of action of
anti-inflammatory drugs. Scand J Rheumatol Suppl 102:9-21, 1996.
20. Gierse JK, Hauser SD, Creely DP, et al: Expression and
selective inhibition of the constitutive and inducible forms of human
cyclo-oxygenase. Biochem J 305:479-484, 1995.
21. Eberhart CE, Coffey RJ, Radhika A, et al: Up-regulation of
cyclooxygenase 2 gene expression in human colorectal adenomas and
adenocarcinomas. Gastroenterology 107:1183-1188, 1994.
22. Kargman SL, O’Neill GP, Vickers PJ, et al: Expression of
prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res
23. Lipsky PE, Isakson PC: Outcome of specific COX-2 inhibition
in rheumatoid arthritis. J Rheumatol 24(suppl 49):9-14, 1997.
24. Simon LS, Lanza FL, Lipsky PE, et al: Preliminary study of
the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitorEfficacy
and safety in two placebo-controlled trials in osteoarthritis and rheumatoid
arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum
25. Geis GS: Update on clinical developments with celecoxib, a
new specific COX-2 inhibitor: What can we expect? J Rheumatol 26:31-36, 1999.
26. Taketo MM: Cyclooxygenase-2 inhibitors in tumorigenesis
(Part II). J Natl Cancer Inst 90:1609-1620, 1998.
27. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of
intestinal polyposis in Apc delta716 knockout mice by inhibition of
cyclooxygenase 2 (COX-2). Cell 87:803-809, 1996.
28. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium
salicylate and aspirin. Science 265:956-959, 1994.
29. Piazza GA, Alberts DS, Hixson LJ, et al: Sulindac sulfone
inhibits azoxymethane-induced colon carcinogenesis in rats without reducing
prostaglandin levels. Cancer Res 57:2909-2915, 1997.
30. Boolbol SK, Dannenberg AJ, Chadburn A, et al:
Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a
murine model of familial adenomatous polyposis. Cancer Res 56:2556-2560, 1996.
31. Reddy BS, Rao CV, Seibert K: Evaluation of cyclooxygenase-2
inhibitor for potential chemopreventive properties in colon carcinogenesis.
Cancer Res 56:4566-4569, 1996.
32. Kawamori T, Rao CV, Seibert K, et al: Chemopreventive
activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon
carcinogenesis. Cancer Res 58:409-412, 1998.
33. Coffey RJ, Hawkey CJ, Damstrup L, et al: Epidermal growth
factor receptor activation induces nuclear targeting of cyclooxygenase-2,
basolateral release of prostaglandins, and mitogenesis in polarizing colon
cancer cells. Proc Natl Acad Sci USA 94:657-662, 1997.
34. Vadlamudi R, Mandal M, Adam L, et al: Regulation of
cyclooxygenase-2 pathway by HER2 receptor. Oncogene 18:305-314, 1999.
35. Tsujii M, DuBois RN: Alterations in cellular adhesion and
apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase
2. Cell 83:493-501, 1995.
36. Pasricha PJ, Bedi A, O’Connor K, et al: The effects of
sulindac on colorectal proliferation and apoptosis in familial adenomatous
polyposis. Gastroenterology 109:994-998, 1995.
37. Steinbach G, Lynch PM, Phillips RKS, et al: The effect of
celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N
Engl J Med 342:1946-1952, 2000.
38. Common Toxicity Criteria: Cancer Therapy Evaluation Program,
Division of Cancer Treatment and Diagnosis, National Cancer Institute, National
Institutes of Health, Department of Health and Human Services, March 1998.
39. Pegg AE: Polyamine metabolism and its importance in
neoplastic growth and as a target for chemotherapy. Cancer Res 48:759-774, 1988.
40. Kingnorth AN, King WWK, Diekema KA, et al: Inhibition of
ornithine decarboxylase with 2-difluoro-methylornithine: Reduced incidence of
dimethylhydrazine-induced colon tumors in mice. Cancer Res 43:2545-2549, 1983.
41. Sinicrope FA, Lemoine M, Xi L, et al: Reduced expression of
cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancer relative
to sporadic cancers. Gastro 117:350-358, 1999.
42. Jarry A, Vallette G, Cassagnau E, et al: Interleukin 1 and
interleukin 1 (beta) converting enzyme (caspase 1) expression in the human
colonic epithelial barrier. Caspase 1 downregulation in colon cancer. Gut
43. Reed JC: Mechanisms of apoptosis avoidance in cancer. Curr
Opin Oncol 11:68, 1999.